全球研究趋势 免疫疗法 对于重复的怀孕损失:一个图书统计学分析
Marcelo Borges Cavalcante1,2,3, Daniel de Sousa Sobral1,2,3, Raíssa Helen de Andrade Praciano2,3
1Graduate Program in Medical Sciences, Universidade de Fortaleza (UNIFOR), Fortaleza, CE, Brazil.
针对复发性流产 (RPL) 的免疫疗法研究显示稳定增长. 目前的重点是免疫机制,肝素,阿司匹林和IVIG经常被研究,而新型治疗需要验证.
科学领域:
- 生殖免疫学 生殖免疫学
- 产科和妇科 产科和妇科
背景情况:
- 复发性流产 (RPL) 影响了大量女性.
- 免疫学因素越来越多地被认为是RPL的关键因素.
- 了解RPL免疫治疗的研究趋势对于推进治疗策略至关重要.
研究的目的:
- 进行对针对重复流产的免疫疗法全球研究的文献计量分析.
- 确定这一领域的关键趋势,有影响力的出版物和研究缺口.
- 从实验性治疗到分子机制的研究演变的映射.
主要方法:
- 从1964年到2024年,对1735篇出版物的图书统计分析.
- 数据来源于科学网络 (WoS) 数据库.
- 关键词同时出现的分析,以确定主题转移.
主要成果:
- 在RPL的免疫治疗中观察到持续的年度研究增长 (1.14%).
- 美国,中国和英国是出版量领先的国家.
- 肝素,阿司匹林和静脉注射免疫球蛋白是研究最多的免疫疗法; 新的治疗方法正在出现.
- 研究已经从早期的实验疗法发展到专注于免疫学和分子机制.
结论:
- 国际合作对于推进RPL的免疫治疗研究至关重要.
- 需要进一步的研究来验证新型免疫疗法的疗效.
- 在通过免疫疗法了解和治疗RPL方面,仍然存在持续的研究差距.
更多相关视频
07:46Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
Published on: October 13, 2023
08:29Author Spotlight: Multiplex Immunohistochemistry for Understanding Immune Regulation by Uterine NK Cells in Pregnancy
Published on: October 25, 2024
相关概念视频
Tumor Immunotherapy
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
